



**We redefine health.  
Through knowledge.**

**Helyx Industries is an integrated biotech group with *proprietary technologies*, developing diagnostic solutions, with a focus on public health, distributed diagnostics and molecular innovation.**

Helyx Industries S.p.A. is an Italian public company with an established footprint of global stakeholders.

We have operations and laboratories in Milan and Trieste (Italy), with a sales track record in more than 20 countries worldwide in the last 10 years.





# HYRIS<sup>®</sup>

by HELYX industries

**Molecular diagnostics and distributed qPCR solutions.**

Hyris develops distributed qPCR platforms, dedicated software and proprietary reagents to enable fast and reliable genetic analysis even outside the traditional laboratory.

Our integrated solutions support hospitals and diagnostic facilities in realizing accurate, standardized and easily replicable molecular workflows.

# VYTRO<sup>®</sup>

by HELYX industries

**Complete PCR solutions for molecular diagnostics.**

Vytro develops IVD-certified PCR kits and reagents to support hospitals, laboratories and diagnostic centres in a wide range of molecular applications.

# MYTHO<sup>®</sup>

by HELYX industries

**Tailored NGS for next-generation molecular insights.**

Mytho develops customized NGS panels, advanced sequencing solutions, and optimized bioinformatics pipelines to support clinical and research applications.

A large and growing number of health and environmental threats are monitored and diagnosed by **genetic testing**.

## **Pope Francis remains in critical condition, Vatican says**

Pontiff had fallen into critical condition, receiving high flows of oxygen and blood transfusions in hospital as he battles complex lung infection

## **Why California declared a state of emergency over bird flu**

The virus has spread for years in wild birds and commercial poultry, and was detected for the first time in US dairy cattle in March

## **Global leaders set first targets to control antimicrobial resistance crisis**


## **Ferrero finds Salmonella again at Belgian factory**

# We enable decentralised genetic testing anywhere at any time, with real-time AI-enabled analytics

We leverage a unique array of vertically integrated patented technologies with top-notch performance in each component of the system.

We hold patents in US, Europe and China for our proprietary technology.

We work in compliance with various quality certifications for medical device manufacturing, cloud privacy, cybersecurity, and security in cloud.




There is an **under-served market area** for mid to low testing volumes.

Our technology provides to distributed locations with mid to low testing volume the same performance and cost efficiency of much larger laboratories.

Typical low testing throughput technologies have very high costs compared to the other technologies used in laboratories with high test turnover.

Our technology enables medium&small labs to access similar cost efficiency of big central labs, with no compromises in performance.



We immensely appreciate the trust that our **global leader partners** demonstrate in our scientific and diagnostic solutions.



Gates Foundation



In September 2020, our solution has been **approved by Health Canada for Point-Of-Care COVID distributed testing**.

The most challenging regulatory approval to obtain, the three holders of an equivalent certification at that time being Abbott Laboratories, Cepheid and Roche.

The Hyris platform for distributed genetic testing has been selected by The Gates Foundation and the Malaria Institute at Johns Hopkins University as **the best technology for malaria surveillance in remote areas**.

During the last 6 years the technology has been successfully piloted and is now being deployed in **30 locations in West Africa**. Expansion to other countries and for other health threats is in planning stages.

We immensely appreciate the trust that our **global leader partners** demonstrate in our scientific and diagnostic solutions.



In partnership with the Icahn School of Medicine at Mount Sinai (NY) and Duke NUS Medical School (Singapore), we developed a test to diagnose long-term cellular immune response to infections.

The research results has been **published in Nature Biotechnology**. The COVID immune response test has been **used by the EU program “Vaccelerate”** to monitor vaccine strategy and execution **and also by the Spanish Government** for a national epidemiological study on SARS-CoV-2 population protection. Synlab, the biggest laboratory chain in Europe, is a client of **test catalog for liquid cancer detection and other oncology-related genetic mutations**.

“A safer connected world is what we dream of.  
Life is what we study so that we can imagine it.  
**Knowledge** is the tool we use to make it happen.”



**Knowledge to Life**

**HELYX INDUSTRIES S.P.A.**

For commercial info:  
**orders@helyx.bio**

For general or product info:  
**info@helyx.bio**

**[www.helyx.bio](http://www.helyx.bio)**